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Abstract
Historically, non–small‐cell lung cancer (NSCLC) patients who are non‐white, have
low incomes, low educational attainment, and non‐private insurance have worse survival. We assessed whether differences in survival were attributable to sociodemographic factors, clinical characteristics at diagnosis, or treatments received. We
surveyed a multiregional cohort of patients diagnosed with NSCLC from 2003 to
2005 and followed through 2012. We used Cox proportional hazard analyses to estimate the risk of death associated with race/ethnicity, annual income, educational attainment, and insurance status, unadjusted and sequentially adjusting for
sociodemographic factors, clinical characteristics, and receipt of surgery, chemotherapy, and radiotherapy. Of 3250 patients, 64% were white, 16% black, 7%
Hispanic, and 7% Asian; 36% of patients had incomes <$20 000/y; 23% had not
completed high school; and 74% had non‐private insurance. In unadjusted analyses,
black race, Hispanic ethnicity, income <$60 000/y, not attending college, and not
having private insurance were all associated with an increased risk of mortality.
Black‐white differences were not statistically significant after adjustment for sociodemographic factors, although patients with patients without a high school diploma
and patients with incomes <$40 000/y continued to have an increased risk of mortality. Differences by educational attainment were not statistically significant after adjustment for clinical characteristics. Differences by income were not statistically
significant after adjustment for clinical characteristics and treatments. Clinical characteristics and treatments received primarily contributed to mortality disparities by
race/ethnicity and socioeconomic status in patients with NSCLC. Additional efforts
are needed to assure timely diagnosis and use of effective treatment to lessen these
disparities.
KEYWORDS
clinical cancer research, healthcare disparities, lung cancer, outcomes research
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IN T RO D U C T ION

Lung cancer is the leading cause of cancer‐related death in
the United States. While comprising 14% of new cancer diagnoses, lung cancer accounts for 27% of cancer‐related deaths
every year.1 Nearly 90% of lung cancer patients are diagnosed
with non–small‐cell lung cancer (NSCLC), and most of these
patients are diagnosed at advanced stages; only 21% survive
more than 5 years.2
Numerous studies have documented disparities in survival among patients diagnosed with NSCLC. In particular, patients who are non‐white,3-5 low income,6,7 insured
by Medicaid,8 or uninsured9-11 have a higher mortality rate
from NSCLC compared with other patients. However, it is
unclear how clinical and treatment differences contribute
to these survival differences. Racial/ethnic minorities are
more likely than white patients to be diagnosed at advanced
stages,12 have a greater number of medical comorbidities,13
and receive fewer appropriate treatments,3,14-17 all of which
may contribute to increased mortality. Similarly, patients insured by Medicaid are diagnosed at a later stage and receive
fewer appropriate treatments than patients with private insurance.7,18 Lower income patients are less likely than higher
income patients to receive curative treatments; they also have
a poorer prognosis.19
Many of the studies examining survival disparities in
patients with NSCLC are single‐center cohort studies that
may not be generalizable or registry studies that lack individual‐level data. The Cancer Care Outcomes Research and
Surveillance (CanCORS) study is a large multiregional observational study of newly diagnosed lung and colorectal
cancer patients that offers the opportunity to avoid these
shortcomings. Previous studies using this dataset have examined racial/ethnic differences in depressive symptoms,20
health‐related quality of life,21 and perceived an unmet need
for supportive services22 among patients with lung cancer,
but these have not examined differences in survival. In this
study, we use the CanCORS dataset to better understand the
factors contributing to survival differences in patients newly
diagnosed with NSCLC.

2
2.1

|

2.2

|

Study cohort

|

Variables

Among 5010 patients with lung cancer, we excluded 40 patients from one study site that did not ascertain survival and
816 patients with small‐cell lung cancer or missing histologic
data. Because we assessed racial/ethnic differences, we also
excluded 904 patients from one study site with >95% non‐
Hispanic white patients, since that site would not inform such
analyses. The final cohort included 3250 patients (Figure 1).

2.3

We grouped variables into three categories: sociodemographic characteristics, clinical characteristics, and

Data overview

Details of the CanCORS study design have been described
elsewhere.23 Briefly, patients newly diagnosed with colorectal or lung cancer were enrolled at study sites across the
country from 2003 to 2005. The sites include 5 geographically defined areas (Iowa, Alabama, and certain counties
in California and North Carolina), 5 integrated healthcare
systems, and 15 Veterans Affairs medical centers. Eligible
patients were identified through rapid case ascertainment by
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cancer registries. Patients were interviewed by telephone a
median of 20 weeks after their diagnosis and provided information about demographics, comorbidities, and treatments
received. Further clinical information was abstracted from
medical records (available for 80% of patients). Abbreviated
and proxy versions of the survey were available to patients
who were unable to complete a full survey or had died by
the time of contact. The CanCORS study population has
been shown to be representative of individuals in the United
States who were diagnosed with lung or colorectal cancer.24
The study protocol was approved by the institutional review
board at all participating institutions.

M ET H OD S
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FIGURE 1

Flow chart of study participants
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treatments. Sociodemographic characteristics included the
primary variables of interest, self‐reported race/ethnicity,
annual household income, educational attainment, and insurance type, as well as sex, age (categorized into approximate
quintiles), marital status, and enrollment in an integrated
health system (including patients from the integrated healthcare system and Veterans Affairs study sites and patients in
geographic sites enrolled in integrated health plans). Clinical
characteristics included a number of self‐reported comorbidities,25 smoking status, and stage at diagnosis. Stage was
assessed based on medical record abstractions or registry
data when medical records were not available. Treatments
included patient‐reported receipt of chemotherapy, surgery,
or radiation. Variables were categorized as in Table 1.
Survival time was measured as days between a patient’s
diagnosis date and date of death; surviving patients were censored on the date last presumed to be alive. Date of death
was obtained from four sources: CanCORS surveys (baseline or follow‐up, approximately 12 months after diagnosis),
medical records, a Social Security Death Index match, or a
National Death Index match. Queries on patient vital status
from medical records or national death records were stopped
at all sites by the end of 2012.
Missing data were infrequent (<6% of observations for
all variables other than income [24%], smoking status [16%],
and comorbidity [14%]). Missing data for all independent
variables were imputed using multiple imputation.26 Vital
status information was complete for all patients in the study
population. Although some CanCORS studies have included
information about social supports and baseline quality of life,
such information was not collected by design for patients who
were deceased at the time of the baseline survey and were
not imputed; thus, those variables were not included in the
analysis.

2.4

|

Statistical analysis

We calculated median survival time from diagnosis using
Kaplan‐Meier estimates and compared differences using log‐
rank tests. We used Cox proportional hazard models to assess
the relative hazard of death. We tested for violations of the
proportional hazards assumption by confirming that the log
hazard‐ratio function for each covariate was constant over
time. The stage at diagnosis variable interfered with the proportional hazards assumption due to 54 patients from one site
coded as “local/regional.” In a sensitivity analysis excluding
those 54 patients, the proportional hazards assumption was
not violated, and the results did not differ (data not shown).
We first estimated the unadjusted hazard ratio for death
based on race/ethnicity, income, education, and insurance
type, as well as age, sex, smoking status, and receipt of care
in an integrated health system. We then conducted three
sequential models. The first model included all of these

MEHTA et al.

sociodemographic variables in a single model. The second
model adjusted for sociodemographic and clinical characteristics at diagnosis, including stage, number of comorbidities,
and smoking status. The third model adjusted for sociodemographic, clinical, and treatment variables, including receipt of
surgery, chemotherapy, and/or radiation. Two‐sided P‐values
<0.05 were considered statistically significant. All models
adjusted standard errors by clustering for study site. Analyses
were performed using Stata version 10 (StataCorp, College
Station, TX).

3

|

RESULTS

Overall, 64% of patients were white, 16% black, 7% Hispanic,
7% Asian, and 5% other race/ethnicity. Among 2459 patients
with income data, 27% of patients had incomes <$20 000/y.
In total, 23% of patients had not completed high school, and
36% had two or more years of college. Only 1.4% of the
population was uninsured at the time of diagnosis, 15% were
insured by Medicaid, dually eligible, or insured by the VA,
53% of patients had Medicare, and 26% had private/health
maintenance organization (HMO) insurance.
The median survival time was 470 days after diagnosis.
Median survival by patient factors is presented in Table 1.

3.1
3.1.1

|

Survival differences

|

Unadjusted analyses

In unadjusted analyses (Table 2), black patients had a slightly
greater risk of death than white patients (HR = 1.05; 95%
CI = 1.00‐1.10; P = 0.05). Hispanic patients tended to have
a greater risk of death (HR = 1.08; 95% CI = 0.99‐1.19;
P = 0.08); patients of Asian and other racial/ethnic descent
did not differ from whites. Patients with lower incomes had
higher mortality than those with incomes above $60 000
(HR = 1.34, 95% CI = 1.16‐1.55, P < 0.001 for incomes
<$20 000; HR = 1.33, 95% CI = 1.18‐1.50, P < 0.001 for
incomes between $20 000 and $40 000; and HR = 1.13; 95%
CI = 1.04‐1.23; P = 0.005 for incomes between $40 000
and $60 000). Patients with less education also had higher
mortality than patients with some college (HR = 1.29, 95%
CI = 1.17‐1.42, P < 0.001 for patients who had not completed high school and HR = 1.13, 95% CI = 1.02‐1.25,
P = 0.02 for high school graduates). Compared with patients
who had private/HMO insurance, patients who were uninsured (HR = 1.39; 95% CI = 1.07‐1.80; P < 0.02), insured
by Medicare (HR = 1.29; 95% CI = 1.11‐1.49; P = 0.001),
or insured by Medicaid/VA/other government insurance
(HR = 1.32; 95% CI = 1.05‐1.66; P < 0.02) had higher mortality. Mortality was lower for women versus men and for
younger versus older patients (Table 2).
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N = 3250
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Characteristics and median survival of patients newly diagnosed with non–small‐cell lung cancer in CanCORS study 2003‐2005,

N

%

Median survivala
(days)

Non‐Hispanic white

2089

64

494

Non‐Hispanic black

512

16

476

Hispanic

241

7

464

Asian

226

7

526

Other/multiracial

162

5

504

20

1

548

>$60 000

454

14

743

$40‐60 000

391

12

487

$20‐40 000

726

23

391

<$20 000

888

27

409

Missing

791

24

611

Some college or more

1182

36

583

High school diploma or vocational training

1253

39

459

732

23

449

83

2

361

26

620

P‐valueb

0.30

Race/ethnicity and socioeconomic variables
Race/ethnicity

Missing
Income

0.001

Education

Non‐high school graduate
Missing

0.001

Insurance
Private or HMO
Uninsured

832
46

1

290

474

15

441

1711

53

473

187

5

446

Male

1851

57

405

Female

1399

43

653

<60

744

23

570

60‐66

619

19

590

67‐72

673

20

486

73‐78

665

20

513

>78

549

17

315

Married/living with partner

1890

58

475

Divorced/separated/never married/widowed

1227

38

489

133

4

874

Integrated

1360

42

497

Non‐integrated

1890

58

490

Medicaid, dual‐eligible, or VA/other
government
Medicare ± supplemental
Missing

0.001

Sex
0.001

Age at diagnosis in years
0.001

Marital status

Missing

0.016

Integrated health system
0.65

(Continues)
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(Continued)
N

%

Median survivala
(days)

P‐valueb

26

2239

0.001

Clinical characteristics
Stage at diagnosis
Stage 1

818

Stage 2

255

8

950

Stage 3a/NOS

365

11

571

Stage 3b

426

13

358

Stage 4

1167

36

196

54

1

290

165

5

407

0 comorbidities

703

22

475

1 comorbidity

833

26

497

2 comorbidities

593

18

457

3 comorbidities

332

10

391

4 + comorbidities

312

10

336

Missing

477

14

787

Never

306

9

587

Former

2193

67

393

Current

246

8

705

Missing

505

16

743

Yes

1208

37

341

No

1973

61

669

69

2

501

Yes

1624

50

470

No

1553

48

574

73

2

441

Yes

1414

44

1489

No

1778

55

256

58

1

537

Local/regional
Missing
Comorbidities

0.001

Smoking status
0.001

Treatments received
Radiation

Missing

0.001

Chemotherapy

Missing

0.001

Surgery

Missing

0.001

VA, veterans affairs; HMO, health maintenance organization; NOS, not otherwise specified.
a
Median survival from Kaplan‐Meier estimates.
b
Based on log‐rank tests.

3.1.2 | Model 1—adjustment for
sociodemographic variables
In the first model, we adjusted for sociodemographic characteristics (race, income, educational attainment, insurance type,
sex, age, and marital status) and observed no difference in mortality by race/ethnicity or insurance type (Table 2). Adjusted
mortality was higher for patients earning <$40 000 yearly

compared with those earning >$60 000 yearly (HR = 1.20, 95%
CI = 1.04‐1.38, P = 0.015 for those earning $20 000‐$40 000;
HR = 1.17, 95% CI = 1.00‐1.36, P = 0.048 for those earning <$20 000). Patients with less educational attainment had
higher mortality than those who attended college (HR = 1.16,
95% CI = 1.06‐1.26, P = 0.001 for those without a high school
diploma; HR = 1.09, 95% CI = 0.99‐1.20, P = 0.065 for those
with a high school diploma or vocational training).

0.92 (0.62‐1.35)

Other

1.20 (1.04‐1.38)
1.17 (1.00‐1.36)

1.33 (1.18‐1.50)
1.34 (1.16‐1.55)

$20‐40 000

<$20 000

1.09 (0.99‐1.20)
1.16 (1.06‐1.26)

1.13 (1.02‐1.25)
1.29 (1.17‐1.42)

Non–high school graduate

1.24 (0.92‐1.66)
1.08 (0.85‐1.36)
1.06 (0.92‐1.22)

1.39 (1.07‐1.80)
1.32 (1.05‐1.66)
1.29 (1.11‐1.49)

Uninsured

Medicaid ± Medicare, VA/other govt

1.00
0.96 (0.92‐1.01)
1.08 (0.99‐1.17)

<60

60‐66

67‐72

Age at diagnosis

1.00

1.00

1.08 (0.96‐1.22)

1.17 (1.04‐1.30)
1.00 (0.94‐1.07)

0.97 (0.89‐1.07)

1.01 (0.96‐1.06)

0.92 (0.88‐0.97)

1.00

0.79 (0.74‐0.84)

1.00

1.14 (0.94‐1.37)

1.11 (0.89‐1.37)

1.04 (0.68‐1.60)

1.00

1.02 (0.87‐1.19)

1.04 (0.91‐1.18)

1.00

1.12 (0.92‐1.37)

1.11 (0.93‐1.33)

1.01 (0.87‐1.18)

1.00

0.80 (0.77‐0.83)

1.00

1.12 (0.94‐1.33)

1.13 (0.90‐1.42)

1.26 (0.88‐1.80)

1.00

1.09 (0.93‐1.28)

1.05 (0.90‐1.23)

1.00

1.18 (0.96‐1.46)

1.17 (1.00‐1.37)

1.04 (0.90‐1.20)

0.97 (0.74‐1.27)

0.82 (0.73‐0.92)

0.83 (0.75‐0.92)
0.95 (0.68‐1.31)

0.97 (0.88‐1.08)

0.88 (0.80‐0.98)

1.00

(Continues)

Model with Sociodemographic,
Clinical, and Treatment Variables
Hazard ratio (95% CI)

1.02 (0.89‐1.17)

0.87 (0.79‐0.97)

1.00

Model with Sociodemographic and
Clinical Variables Hazard ratio (95%
CI)

1.00

1.00
0.77 (0.70‐0.83)

1.00
0.77 (0.70‐0.85)

Male

Female

Sex

Additional sociodemographic variables

Medicare ± supplemental

1.00

1.00

Private insurance/HMO

Insurance

1.00

1.00

Some college or more

High school diploma or vocational
training

Education

1.00
1.06 (0.98‐1.15)

1.00
1.13 (1.04‐1.23)

>$60 000

0.93 (0.66‐1.30)

0.97 (0.82‐1.14)

$40‐60 000

Income

0.95 (0.82‐1.09)

Asian

1.07 (0.94‐1.21)

1.00 (0.91‐1.09)

1.05 (1.00‐1.10)
1.08 (0.99‐1.19)

Non‐Hispanic black

Hispanic

1.00

1.00

Model with Sociodemographic
Variables Hazard ratio (95% CI)

Non‐Hispanic white

Race/ethnicity

Unadjusted Association
Hazard ratio (95% CI)

Adjusted associations of characteristics with survival in patients newly diagnosed with non–small‐cell lung cancer

Race/ethnicity and socioeconomic variables

Variable

TABLE 2
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1.02 (0.96‐1.08)

2.67 (2.34‐3.04)
3.66 (2.87‐4.67)
6.35 (5.03‐8.03)
2.89 (2.24‐3.74)
3.45 (2.35‐5.07)

2.46 (2.08‐2.91)
3.39 (2.49‐4.61)
5.73 (4.49‐7.31)
2.78 (2.27‐3.40)
3.18 (2.04‐4.94)

Stage 3a/NOS

Stage 3b

Stage 4

Local/regional

1.36 (1.08‐1.73)

1.32 (1.06‐1.65)

0.96 (0.77‐1.21)

0.97 (0.80‐1.14)

  

Radiation

Treatments received

0.86 (0.61‐1.22)

1.12 (1.04‐1.23)

1.17 (0.98‐1.39)

Current

1.00

1.00
1.16 (1.07‐1.25)

1.00

Former

1.32 (1.04‐1.67)

1.15 (0.99‐1.34)

Never

Smoking status

1.11 (0.94‐1.31)

1.08 (0.89‐1.32)

4 + comorbidities

1.12 (1.02‐1.23)

3 comorbidities

1.12 (1.00‐1.25)

1.06 (0.95‐1.18)

2 comorbidities

1.11 (1.00‐1.22)

1.03 (0.92‐1.15)

1 comorbidity

1.00

2.74 (1.79‐4.20)

2.27 (1.65‐3.11)

4.91 (3.60‐6.72)

3.05 (2.31‐4.03)

2.34 (2.01‐2.73)

1.98 (1.49‐2.64)

1.00

0.90 (0.81‐1.01)

1.00

1.00 (0.90‐1.11)

1.00

1.27 (1.07‐1.52)

1.11 (0.92‐1.33)

Model with Sociodemographic,
Clinical, and Treatment Variables
Hazard ratio (95% CI)

1.09 (0.97‐1.24)

1.00

0 comorbidities

Comorbidities
1.00

1.88 (1.54‐2.31)

1.81 (1.47‐2.23)

Stage 2

Missing

1.00

0.95 (0.83‐1.08)

1.00

1.02 (0.92‐1.13)

1.00

0.97 (0.80‐1.18)

1.00

1.02 (0.96‐1.09)

1.00

1.69 (1.51‐1.90)

1.25 (1.06‐1.48)

Model with Sociodemographic and
Clinical Variables Hazard ratio (95%
CI)

Stage 1

Stage

Clinical characteristics

1.00
1.02 (0.86‐1.21)

Non–integrated

Integrated

Integrated health system

Divorced/separated/never married

1.46 (1.31‐1.62)

1.56 (1.41‐1.73)
1.00

1.09 (0.99‐1.19)

1.16 (1.01‐1.34)

1.00

Model with Sociodemographic
Variables Hazard ratio (95% CI)

Unadjusted Association
Hazard ratio (95% CI)

Married/living with partner

Marital status

>78

73‐78

(Continued)

|

Variable

TABLE 2

5838
MEHTA et al.

  

1.00

2.21 (1.90‐2.58)

1.00

1.65 (1.51‐1.81)

0.90 (0.78‐1.04)

1.00

In the second model, we adjusted for sociodemographic and
clinical characteristics, including stage at diagnosis, number
of comorbidities, and smoking status (Table 2). After this
adjustment, black patients (HR: 0.87; 95% CI = 0.79‐0.97;
P = 0.01) and Asian patients (HR: 0.83; 95% CI = 0.75‐0.92;
P < 0.001) had lower mortality than non‐Hispanic white
patients. Patients earning $40 000‐$60 000 had similar mortality as those earning >$60 000. Patients earning
$20 000‐$40 000 had higher mortality than those earning
>$60 000 (HR = 1.17; 95% CI = 1.00‐1.37; P = 0.049). The
difference in mortality by educational attainment was no
longer statistically significant.

After adjustment for treatments received, including chemotherapy, surgery, or radiation, Asian and black patients continued to have lower mortality compared with non‐Hispanic
white patients (Table 2). After this adjustment, there was no
longer any difference in mortality by income. In this fully
adjusted model, mortality was higher for men versus women,
patients aged >78 versus <60, patients with advanced‐
stage cancer, and patients with one or more comorbidities.
Mortality was also higher for patients who did not undergo
chemotherapy or surgery.

Model with Sociodemographic
Variables Hazard ratio (95% CI)

VA, Veterans Affairs; HMO, health maintenance organization.
Bold values represent statistically significant associations (P < 0.05).

1.00

3.57 (3.14‐4.06)

Yes

No

Surgery

1.00

0.88 (0.75‐1.03)

Yes

No

No

Yes

Variable

Chemotherapy

0.64 (0.55‐0.75)

4

1.00

Unadjusted Association
Hazard ratio (95% CI)

5839

3.1.4 | Model 3—adjustment
for sociodemographic, clinical, and
treatment variables

(Continued)

TABLE 2

|

3.1.3 | Model 2—adjustment for
sociodemographic and clinical variables

Model with Sociodemographic and
Clinical Variables Hazard ratio (95%
CI)

Model with Sociodemographic,
Clinical, and Treatment Variables
Hazard ratio (95% CI)

MEHTA et al.
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DISCUSSION

Consistent with previous studies examining disparities in
care and outcomes for patients with NSCLC, we found that
race/ethnicity, income, educational status, and insurance
status were associated with higher mortality among patients
with NSCLC. However, we found that these differences were
no longer evident after adjusting for sociodemographic, clinical, and treatment variables.
In unadjusted analysis, black patients had a slightly
higher risk of mortality compared with white patients,
but the difference was small (median survival differences—18 days). This difference was notably smaller than
the median differences by education (4.5 months), income
(11 months), and insurance coverage (11 months), which
likely represent clinically important disparities. The higher
risk of mortality for black versus white patients was no longer evident after adjustment for other sociodemographic
characteristics, including income, education, and insurance. In fact, after adjustment for differences in cancer
stage and comorbidities, black patients had lower mortality

5840
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than white patients. These findings differ from studies
that show higher 5‐year mortality for black and Hispanic
patients compared with non‐Hispanic white patients.3-5,27
However, our population differs from these studies in that
we have a multiregional cohort with a relatively small unadjusted difference in mortality between black and white
patients, and we also had rich, self‐reported data about patients’ sociodemographic status. Other studies have documented that black patients with lung cancer have similar
or better mortality than white patients after adjustment for
sociodemographic factors28 or in settings with equal‐access health systems such as the military.29,30 As a whole,
this suggests that differences in access to treatment and
timely diagnosis may play an important role in survival
differences by race/ethnicity. Asian patients in this study
had similar mortality as white patients in the unadjusted
analysis, but had lower mortality than white patients after
adjustment for clinical factors, including stage. We lacked
data on molecular markers in our population; however, the
better survival relative to white patients may reflect the
higher frequency of favorable EGFR mutations in Asian
patients with NSCLC.31
Patients earning below $60 000 per year had a 13‐34%
higher risk of mortality than those earning more than
$60 000. This difference was diminished in part by adjustment for more advanced stage at diagnosis and greater
comorbidity burden among lower income individuals, and
further diminished by adjustment for treatment. Previous
studies have shown that low‐income patients are often diagnosed at a later stage than high‐income patients, and late‐
stage disease is a strong predictor of poorer outcomes.32,33
Patients who have low income may have worse outcomes
for reasons not captured by stage at diagnosis or number of
comorbidities. These may include severity of comorbidities, lack of social support, or even intensity of treatments
received. Identifying strategies to ensure access to needed
care in addition to early diagnosis will be important to addressing income‐related differences in care.
We also observed that patients with less education had
13‐29% increased risk of mortality than patients with more
education. This difference was no longer evident after adjustment for clinical features at the time of diagnosis. Other
studies have shown that lower educational attainment predicts poorer outcomes in patients with NSCLC.34 Our study
extends such work by assessing patient‐reported educational
attainment rather than imputing educational attainment by
geocoded address data at an area‐ or census‐tract level. Our
study also builds on prior work showing that patients with
lower levels of education are diagnosed at later stages,35 a
plausible mechanism leading to higher mortality.
The National Academy of Medicine defines health disparities as differences in care or outcomes that are not due
to differences in clinical appropriateness or informed patient
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preferences.36 Although we had rich clinical data, we lacked
information to allow us to fully understand whether the differences that persisted after adjustment for stage at diagnosis,
comorbidities, and treatments received were related to differences in access and receipt of high‐quality care or other
factors like patient preferences and clinical appropriateness.
However, given the magnitude of survival differences demonstrated in the unadjusted analysis, these likely represent clinically relevant disparities that are explained by clinical and
treatment‐related factors.
Our study’s strengths include its diverse and multiregional
patient population from across the United States as well as
the rich clinical data from patients, medical records, and
cancer registries. However, our study has several limitations.
First, patients were diagnosed more than a decade ago, and
we cannot be certain that findings would be similar in current
cohorts, although other evidence suggests that racial/ethnic
and sociodemographic disparities remain a problem for patients diagnosed with lung cancer.27,37-39 Second, our patient
population had a lower rate of uninsurance than the general
US population. This may reflect the geographic regions we
studied. It is also possible that patients without insurance
were less likely to enroll in the study, although we recruited
patients primarily from population‐based registries, and our
study cohort was representative of patients in these areas with
newly diagnosed cancers.24 Lastly, we ascertained treatments
based on patient report, although other evidence suggests that
patients can accurately report major cancer treatments such
as surgery, radiation, and chemotherapy.40,41
In conclusion, we observed higher mortality for NSCLC
for black versus white patients, patients with non‐private insurance, and patient with lower levels of educational attainment and income. The difference between black and white
patients in survival was no longer evident after adjustment
for sociodemographic factors, and black patients had better
outcomes than white patients after adjustment for clinical
characteristics and treatments received. Clinical characteristics at the time of diagnosis contributed to higher mortality for patients with less education and income. Different
treatments received also contributed to higher mortality for
low‐income individuals. Our study suggests that disparities
in NSCLC mortality may be diminished with efforts to ensure early diagnosis and effective treatments.
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